Manager × security

SECTOR GAMMA AS BMRN holdings history

Who else holds this security? →

BIOMARIN PHARMACEUTICAL INC · CUSIP 09061G101 · CIK 1475373

This is the oldest quarter open without an account, so changes against the quarter before it are withheld. Sign in to see them.
Citable facts

As of 2026-06-30, SECTOR GAMMA AS reported 294.92K BMRN (shares), valued at $16.88M, or 3.66% of its reported non-derivative portfolio. Filed 2026-08-12.

Verify history & sources →
Portfolio weight and quantity history
Reported portfolio weight
3.66%
Shares
294.92K
294,918
Reported value
$16.88M
USD

Shares increased 22.92%; reported value increased 24.51%, and weight changed +0.46 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.

Left: % · Right: Shares · Independently scaled axes

Exact data and methodology

Axes scale independently; a crossing does not mean equal values. Weight uses each quarter's total reported non-derivative value. Same CUSIP; missing quarters are gaps, not zero. Revised history may include later disclosures.

QuarterWeightQuantitySource
Q2 20263.66%294,918SEC filing ↗Filed Aug 12, 2026
Q1 20263.20%239,918SEC filing ↗Filed May 7, 2026
Q4 20252.69%198,505SEC filing ↗Filed Feb 12, 2026
Q3 20252.36%175,852SEC filing ↗Filed Oct 31, 2025
Q2 20252.20%122,348SEC filing ↗Filed Jul 31, 2025
Q1 20253.11%137,348SEC filing ↗Filed May 13, 2025
Q4 20244.91%217,348SEC filing ↗Filed Feb 11, 2025
Q3 20244.06%190,348SEC filing ↗Filed Nov 13, 2024
Q2 20241.95%63,348SEC filing ↗Filed Aug 9, 2024
Q1 20242.00%81,416SEC filing ↗Filed May 8, 2024
Q4 20232.02%86,247SEC filing ↗Filed Feb 5, 2024

History & evidence by quarter

QuarterWeightQuantityValueChange explainedSource
Q4 20232.02%86,247$8.32MThe prior quarter is outside the free window. Sign in for the comparison.SEC filing ↗
Filed Feb 5, 2024
Q1 20242.00%81,416$7.11MShares decreased 5.60%; reported value decreased 14.49%, and weight changed -0.02 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 8, 2024
Q2 20241.95%63,348$5.22MShares decreased 22.19%; reported value decreased 26.66%, and weight changed -0.05 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Aug 9, 2024
Q3 20244.06%190,348$13.38MShares increased 200.48%; reported value increased 156.54%, and weight changed +2.11 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Nov 13, 2024
Q4 20244.91%217,348$14.29MShares increased 14.18%; reported value increased 6.78%, and weight changed +0.85 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Feb 11, 2025
Q1 20253.11%137,348$9.71MShares decreased 36.81%; reported value decreased 32.04%, and weight changed -1.80 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 13, 2025
Q2 20252.20%122,348$6.73MShares decreased 10.92%; reported value decreased 30.73%, and weight changed -0.91 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Jul 31, 2025
Q3 20252.36%175,852$9.52MShares increased 43.73%; reported value increased 41.61%, and weight changed +0.16 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Oct 31, 2025
Q4 20252.69%198,505$11.80MShares increased 12.88%; reported value increased 23.87%, and weight changed +0.33 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Feb 12, 2026
Q1 20263.20%239,918$13.55MShares increased 20.86%; reported value increased 14.88%, and weight changed +0.51 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 7, 2026
Q2 20263.66%294,918$16.88MShares increased 22.92%; reported value increased 24.51%, and weight changed +0.46 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Aug 12, 2026
SECTOR GAMMA AS · BIOMARIN PHARMACEUTICAL INC

Take these holdings further.

This page includes 11 of 11 reported holdings. Sign in to look up the full history beyond 3 years, use advanced screening & filtering, download CSV, and get the complete set through the Akkru API.

  • Download CSV
  • Earlier quarters
  • Advanced screening & filtering
  • API & AI access
Already have an account?

+ New accounts get free API credits to explore data beyond ownership filings.

For AI agents & developers

The initial HTML of this page carries its exact data as script#research-data (JSON): values, units, scope, preview limits and SEC sources. Read it directly, no script or API key needed; script#research-access says what needs an account.

Without an account: the last 3 years, with the row caps stated on the page. A free account opens all history on file on these pages and the CSV of what a page shows. Rows beyond the caps and bulk retrieval go through the authenticated API / MCP.

MCP  https://api.akkrudata.ai/mcp

get_institutional_portfolio
{"cik":"1475373","quarter":"2026Q2","cusip":"09061G101"}

get_institutional_manager_history
{"cik":"1475373","page_size":100}

Connect to MCP with OAuth and follow the returned pagination. Credits and usage limits depend on the account.

MCP endpoint
https://api.akkrudata.ai/mcp
API / MCP documentation
/documents
llms.txt
/llms.txt
Sources, coverage & how to read this data

Figures are as reported to the SEC and merged with later amendments where Akkru could match them. Preview limits apply to what is listed, not to the totals, which come from the complete reported data. Nothing is zero-filled: a missing quarter or month is shown as missing.

13F reports quarter-end long positions in securities traded on US exchanges, filed by managers holding at least $100 million of such securities; it is not the manager's full portfolio, not assets under management, and value changes are not returns. Weights use the reported total value as denominator. Option rows show notional value, not premium or net exposure. Amendments are merged into the quarter when Akkru could match them.